drugset / Trial / NCT06510465

Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)

NCT06510465

Phase 2 Not yet recruiting 143 enrolled RenJi Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is a prospective, multi-center, single-arm, two-cohort, exploratory study, aiming to explore the effectiveness and safety of neoadjuvant treatment with weekly utidelone combined with cisplatin in breast cancer patients.

Timeline

Start
2024-08-01
Primary completion
2027-03-31
Completion
2032-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 25 mg/m2 Intravenous
Subject Epothilone D Small molecule 50 mg/m2 Intravenous
Subject Pertuzumab Monoclonal antibody 420 mg Intravenous
Subject Trastuzumab Monoclonal antibody 2 mg/kg Intravenous
Subject Trastuzumab Monoclonal antibody 6 mg/kg Intravenous
Subject Trastuzumab Monoclonal antibody 600 mg Intravenous

Indications